중추신경계 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 약물 종류별, 적응증별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 및 경쟁 상황(2021-2031년)
Central Nervous System Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Application, By Route of Administration, By End User, By Distribution Channel, By Region & Competition, 2021-2031F
상품코드:1914576
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 중추신경계 치료제 시장은 2025년 1,152억 1,000만 달러에서 2031년까지 1,824억 2,000만 달러로 확대되고, CAGR 7.96%를 기록할 것으로 예측됩니다.
이들 치료제는 알츠하이머병, 우울증 등 뇌와 척수에 영향을 미치는 신경계 및 정신과적 질환을 치료하기 위한 의약품을 통한 개입으로 구성되어 있습니다. 이러한 성장을 이끄는 주요 요인으로는 급속한 고령화와 이에 따른 신경퇴행성 질환의 증가, 그리고 효과적인 약물 치료에 대한 수요를 뒷받침하는 정신건강 문제에 대한 전 세계적인 인식의 증가를 들 수 있습니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
1,152억 1,000만 달러
시장 규모 : 2031년
1,824억 2,000만 달러
CAGR : 2026-2031년
7.96%
가장 빠르게 성장하는 부문
다발성 경화증
최대 시장
아시아태평양
한편, 업계는 혈액뇌장벽을 통과할 수 있는 약물 개발에 따른 과학적 복잡성으로 인해 심각한 장벽에 직면해 있습니다. 이러한 장벽은 임상시험의 높은 실패율의 원인이 되는 경우가 많으며, 이러한 복잡성은 개발 비용의 증가와 개발 기간의 장기화로 이어져 시장 성장을 제약할 수 있습니다. 유럽제약단체연합회(EFPIA)는 이러한 과제를 극복하기 위해 투입되는 막대한 자금에 대해 유럽제약협회(EFPIA)는 2024년 유럽 전역에서 연구개발형 제약 업계가 550억 유로를 연구개발에 투자할 것으로 추정하고 있습니다.
시장 촉진요인
전 세계적으로 신경 및 정신 질환의 유병률 증가는 세계 중추신경계 치료제 시장의 성장을 이끄는 주요 요인으로 작용하고 있습니다. 평균 수명이 연장됨에 따라 신경퇴행성 질환의 누적 위험이 증가하여 장기적인 약물 관리가 필요한 환자층이 확대되고 있습니다. 이러한 추세는 우선적인 치료 접근이 필요한 정신질환의 광범위한 발생으로 인해 더욱 증폭되고 있습니다. 이러한 건강 위기의 심각성은 2024년 3월 건강지표평가연구소(IHME)가 'The Lancet Neurology'지에 발표한 연구 결과에서 잘 드러납니다. 이 조사에 따르면, 전 세계적으로 34억 명 이상이 신경 질환의 영향을 받고 있으며, 이는 전 세계 건강 장애와 장애의 주요 원인으로 추정되고 있습니다.
한편, 강력한 임상 개발 파이프라인과 신경과학 연구개발에 대한 자본 투자 증가가 시장을 견인하고 있습니다. 제약사들은 특히 조현병이나 알츠하이머병과 같은 복잡한 질환에 대한 새로운 작용기전을 확보하기 위해 전략적 합병과 제휴를 적극적으로 추진하고 있으며, 이를 통해 치료제의 상용화를 가속화하고 혈액뇌관문 투과성과 같은 장벽에 대한 대응이 진행되고 있습니다. 예를 들어, 브리스톨 마이어스 스퀴브는 2023년 12월 정신의학 분야 포트폴리오 강화를 위해 카르나 테라퓨틱스를 140억 달러에 인수하기로 합의했습니다. 한편, 알츠하이머병 협회는 2024년 알츠하이머병 및 기타 치매를 앓고 있는 미국인들의 총 의료비가 3,600억 달러에 달할 것으로 예상하고 있으며, 효과적인 치료법에 대한 막대한 상업적 잠재력을 강조하고 있습니다.
시장의 과제
세계 중추신경계 치료제 시장의 주요 제약요인은 혈액뇌장벽을 효과적으로 통과할 수 있는 약물의 개발이 과학적으로 어렵다는 점입니다. 이 생물학적 필터는 많은 잠재적 치료제가 뇌 내 표적 부위에 도달하는 것을 선택적으로 억제하기 때문에 전임상 데이터가 양호하더라도 임상시험에서 화합물의 인체 안전성이나 유효성이 입증되지 않는 경우가 빈번하게 발생하여 실패율이 매우 높습니다. 그 결과, 기업은 개발 기간이 길어지고, 신경학 연구 이니셔티브에 따른 높은 재정적 위험을 감수해야 합니다.
이러한 리스크를 관리하기 위해 필요한 막대한 자원은 시장 진입 기업의 수를 제한하고, 성공적인 의약품의 수익률을 압박합니다. 이는 소규모 사업체에게는 장벽이 되고, 새로운 치료법의 출시가 지연되는 결과를 초래하고 있습니다. 이러한 문제의 심각성은 생명공학혁신기구(BIO)의 데이터를 통해서도 알 수 있습니다. 이 기관은 2024년 신규 치료제 후보물질의 임상개발 성공률이 약 6.7%라고 보고했습니다. 이러한 낮은 승인 가능성은 성공률이 높은 치료 분야에 비해 중추신경계(CNS) 분야에 대한 투자를 억제하는 경향이 있어 전체 시장 확대를 저해하는 요인으로 작용하고 있습니다.
시장 동향
시장의 중요한 변화는 신경퇴행성 질환에 대한 질병 변형 생물학적 제제로의 전환으로, 증상 완화에서 알츠하이머병과 같은 근본적인 병태에 대한 표적 치료로 초점이 이동하고 있습니다. 이러한 추세는 플라크 침착을 제거하고 인지 기능 저하를 지연시키는 항아밀로이드 단클론항체의 상용화에 의해 주도되고 있으며, 이는 수익 모델을 변화시키고 진단 및 투약 인프라에 대한 투자를 촉진하는 진전입니다. 이러한 치료법의 급속한 보급을 반영하여, 에자이 주식회사는 2024년 11월 보도자료를 통해 알츠하이머병 치료제 '레켄비'의 2025년 3월기 세계 매출이 425억엔에 달할 것이라는 전망을 발표하였습니다.
동시에 중추신경계(CNS) 표적 발굴에 인공지능(AI)을 활용함으로써 유망한 약물 후보물질 발굴을 가속화하고, 신경질환 치료제 개발의 기존 실패율을 개선하고 있습니다. 제약사들은 대규모 생물학적 데이터세트를 분석하는 머신러닝 알고리즘을 활용하기 위해 AI 전문 기업과의 협업을 강화하고 있습니다. 이를 통해 임상시험 전에 약물과 표적의 상호작용을 정밀하게 예측하고 분자구조를 최적화할 수 있습니다. 이 분야에 대한 대규모 자금 유입을 보여주는 사례로, 포메이션 바이오는 2024년 6월 보도자료를 통해 AI 기반 신약개발 역량 강화를 위해 사노피의 참여로 3억 7,200만 달러의 시리즈 D 펀딩을 확보했다고 발표했습니다.
용도별(신경퇴행성 질환, 정신 보건·외상, 신경혈관 질환, 감염증, 중추신경계 암, 기타)
투여 경로별(경구, 비경구, 기타)
최종사용자별(병원, 진료소, 진단 검사실, 기타)
유통 채널별(병원 약국, 온라인 약국, 소매 약국)
지역별
기업별(2025)
시장 맵
제6장 북미의 중추신경계 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 중추신경계 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 중추신경계 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 중추신경계 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 중추신경계 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 중추신경계 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
Pfizer Inc.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis International AG
Roche Holding AG
Bristol-Myers Squibb Company
Sanofi S.A.
GlaxoSmithKline plc
AbbVie Inc.
AstraZeneca plc
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Central Nervous System Therapeutics Market is projected to expand from USD 115.21 billion in 2025 to USD 182.42 billion by 2031, reflecting a CAGR of 7.96%. These therapeutics consist of pharmaceutical interventions aimed at treating neurological and psychiatric conditions affecting the brain and spinal cord, such as Alzheimer's disease and depression. Key factors fueling this growth include rapidly aging global demographics and the resulting increase in neurodegenerative diseases, alongside a rising worldwide awareness of mental health issues that sustains demand for effective pharmacological treatments.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 115.21 Billion
Market Size 2031
USD 182.42 Billion
CAGR 2026-2031
7.96%
Fastest Growing Segment
Multiple Sclerosis
Largest Market
Asia Pacific
Conversely, the industry faces significant obstacles due to the scientific intricacies involved in developing drugs capable of crossing the blood-brain barrier, a hurdle that frequently contributes to high failure rates in clinical trials. This complexity leads to increased development costs and extended timelines, which can constrain market growth. Highlighting the massive financial resources dedicated to navigating these challenges, the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical industry invested €55 billion in research and development across Europe in 2024.
Market Driver
The rising global prevalence of neurological and psychiatric disorders serves as the primary engine for growth in the Global Central Nervous System Therapeutics Market. As life expectancy rises, the cumulative risk of neurodegenerative conditions increases, creating a larger patient population requiring long-term pharmaceutical management, a trend further amplified by the widespread occurrence of mental health disorders that necessitate prioritized therapeutic access. The magnitude of this health crisis was highlighted by a study published in 'The Lancet Neurology' by the Institute for Health Metrics and Evaluation in March 2024, which estimated that over 3.4 billion people worldwide are affected by neurological conditions, making them the leading cause of global ill health and disability.
Concurrently, the market is boosted by a strong clinical pipeline and increased capital investment in neuroscience research and development. Pharmaceutical companies are actively pursuing strategic mergers and partnerships to acquire novel mechanisms of action, particularly for complex conditions like schizophrenia and Alzheimer's disease, thereby accelerating the commercialization of treatments and addressing barriers such as blood-brain barrier penetration. For instance, Bristol Myers Squibb agreed to acquire Karuna Therapeutics for an equity value of $14 billion in December 2023 to enhance its psychiatry portfolio, while the Alzheimer's Association projected in 2024 that total care payments for Americans with Alzheimer's and other dementias would reach $360 billion, underscoring the immense commercial potential for effective therapies.
Market Challenge
A major constraint on the global central nervous system therapeutics market is the scientific difficulty of creating drugs that can successfully traverse the blood-brain barrier. This biological filter selectively blocks many potential treatments from reaching targeted areas in the brain, resulting in exceptionally high attrition rates during clinical trials where compounds frequently fail to prove safety or efficacy in humans despite favorable preclinical data. Consequently, companies are compelled to lengthen development timelines and accept higher financial risks associated with neurological research initiatives.
The significant resources needed to manage these risks restrict the number of market participants and compress profit margins for successful drugs, creating hurdles for smaller entities and slowing the launch of new therapies. The severity of these challenges is evident in data from the Biotechnology Innovation Organization, which reported in 2024 that the clinical development success rate for new therapeutic candidates was approximately 6.7 percent. This low likelihood of approval tends to deter investment in CNS compared to therapeutic areas with higher success rates, thereby inhibiting the overall expansion of the market.
Market Trends
A pivotal transformation in the market is the shift toward disease-modifying biologics for neurodegenerative disorders, moving the focus from symptomatic relief to targeting underlying pathologies like Alzheimer's disease. This trend is led by the commercialization of anti-amyloid monoclonal antibodies capable of clearing plaque deposits and slowing cognitive decline, a development that is altering revenue models and spurring investment in diagnostic and infusion infrastructure. Reflecting the rapid uptake of these therapies, Eisai Co., Ltd. projected in a November 2024 press release that global revenue for its Alzheimer's treatment, Leqembi, would reach JPY 42.5 billion for the fiscal year ending March 2025.
Simultaneously, the adoption of artificial intelligence for CNS target identification is expediting the discovery of viable drug candidates and addressing historic failure rates in neurological development. Pharmaceutical firms are increasingly collaborating with AI-specialized companies to utilize machine learning algorithms that analyze massive biological datasets, enabling precise prediction of drug-target interactions and optimization of molecular structures prior to clinical testing. Demonstrating the significant capital flowing into this area, Formation Bio announced in a June 2024 press release that it secured $372 million in Series D financing, with participation from Sanofi, to enhance its AI-driven drug development capabilities.
Key Market Players
Pfizer Inc.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis International AG
Roche Holding AG
Bristol-Myers Squibb Company
Sanofi S.A.
GlaxoSmithKline plc
AbbVie Inc.
AstraZeneca plc
Report Scope
In this report, the Global Central Nervous System Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Central Nervous System Therapeutics Market, By Drug Class
Multiple Sclerosis
Antipsychotic
Antiepileptics
Analgesics & Anesthetics
Anti-Parkinson
Others
Central Nervous System Therapeutics Market, By Application
Neurodegenerative Diseases
Mental Health and Trauma
Neurovascular Diseases
Infectious Diseases
CNS Cancer
Others
Central Nervous System Therapeutics Market, By Route of Administration
Oral
Parenteral
Others
Central Nervous System Therapeutics Market, By End User
Hospital
Clinics
Diagnostic Laboratories
Others
Central Nervous System Therapeutics Market, By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Central Nervous System Therapeutics Market, By Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Central Nervous System Therapeutics Market.
Available Customizations:
Global Central Nervous System Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Central Nervous System Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)
5.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)
5.2.3. By Route of Administration (Oral, Parenteral, Others)
5.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)
5.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Central Nervous System Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Application
6.2.3. By Route of Administration
6.2.4. By End User
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Central Nervous System Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Application
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By End User
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Central Nervous System Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Application
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By End User
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Central Nervous System Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Application
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By End User
6.3.3.2.5. By Distribution Channel
7. Europe Central Nervous System Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Application
7.2.3. By Route of Administration
7.2.4. By End User
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Central Nervous System Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Application
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End User
7.3.1.2.5. By Distribution Channel
7.3.2. France Central Nervous System Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Application
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End User
7.3.2.2.5. By Distribution Channel
7.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Application
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End User
7.3.3.2.5. By Distribution Channel
7.3.4. Italy Central Nervous System Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Application
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By End User
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Central Nervous System Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Application
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By End User
7.3.5.2.5. By Distribution Channel
8. Asia Pacific Central Nervous System Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Application
8.2.3. By Route of Administration
8.2.4. By End User
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Central Nervous System Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Application
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End User
8.3.1.2.5. By Distribution Channel
8.3.2. India Central Nervous System Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Application
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End User
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Central Nervous System Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Application
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End User
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Central Nervous System Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Application
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By End User
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Central Nervous System Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Application
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By End User
8.3.5.2.5. By Distribution Channel
9. Middle East & Africa Central Nervous System Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Application
9.2.3. By Route of Administration
9.2.4. By End User
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Central Nervous System Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Application
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By End User
9.3.1.2.5. By Distribution Channel
9.3.2. UAE Central Nervous System Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Application
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By End User
9.3.2.2.5. By Distribution Channel
9.3.3. South Africa Central Nervous System Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Application
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By End User
9.3.3.2.5. By Distribution Channel
10. South America Central Nervous System Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Application
10.2.3. By Route of Administration
10.2.4. By End User
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Central Nervous System Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Application
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By End User
10.3.1.2.5. By Distribution Channel
10.3.2. Colombia Central Nervous System Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Application
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By End User
10.3.2.2.5. By Distribution Channel
10.3.3. Argentina Central Nervous System Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Application
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By End User
10.3.3.2.5. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Central Nervous System Therapeutics Market: SWOT Analysis
